Evidence-Based Oncology
Will be published approx. on 25. January 2030
Book
Hardback
760 pages
978-1-4051-6003-2 (ISBN)
Description
Evidence-based Oncology was published at ASCO in May 2003 and immediately made a big impact on the world of clinical oncology. Belonging to the BMJ Books series of evidence-based textbooks, this internationally authored text provides guidance to clinical oncologists on the best evidence for screening and treatment of the major malignancies. With authoritative reviews based on Cochrane and other systematic reviews and high quality trials, the recommendations in this book provide unique information for treatment options in the context of the individual patient s needs. Need for a second edition In the field of evidence-based medicine more than any, the need for fully up to date evidence is paramount. The recommendations in this book have remained current over the past three years, but clinical oncology has moved on, and a wider issues have come to the fore which need addressing. Rather than rely on short update commentaries on the website, the editors have decided they need to produce an entirely new edition in which the wider management issues of diagnosis, patient choice, health policy and health economics are covered.
The new edition also provides an opportunity to add more chapters on conditions where sufficient evidence has emerged for treatment recommendations to be made. Hence this second edition will be a different, richer and more comprehensive book than the first, and more in keeping with health care policy for the 21st century. Features of the 2nd edition 30 additional new chapters New section on care of the elderly New section on palliative care New section on delivery of care More emphasis on diagnosis and screening More emphasis on developing country issues Relevant for health care providers and managed care as well as clinicians Attractive new layout and cover design Electronic delivery either via CDRom or the Web
The new edition also provides an opportunity to add more chapters on conditions where sufficient evidence has emerged for treatment recommendations to be made. Hence this second edition will be a different, richer and more comprehensive book than the first, and more in keeping with health care policy for the 21st century. Features of the 2nd edition 30 additional new chapters New section on care of the elderly New section on palliative care New section on delivery of care More emphasis on diagnosis and screening More emphasis on developing country issues Relevant for health care providers and managed care as well as clinicians Attractive new layout and cover design Electronic delivery either via CDRom or the Web
More details
Series
Language
English
Place of publication
Chicester
United Kingdom
Publishing group
John Wiley and Sons Ltd
Target group
Professional and scholarly
ISBN-13
978-1-4051-6003-2 (9781405160032)
Copyright in bibliographic data is held by Nielsen Book Services Limited or its licensors: all rights reserved.
Schweitzer Classification
Persons
Chris Williams is Clinical Director of the Bristol Haematology and Oncology Centre, Bristol, UK and former Editor of the Cochrane Oncology Review Group Paul Cornes is Consultant Clinical Oncologist at the Bristol Haematology and Oncology Centre and was previously at the Royal Marsden Hospital in London, UK
Content
Contents of the 2nd edition. Introduction: Explanation of the philosophy, structure and ways to use of the book Section 1: Principles of evidenced-based medicine. 1] Searching for evidence. 2] Appraising the literature. 3] Economic evaluation of cancer treatments. 4] Evidence-based approach to diagnostic techniques. 5] Strengths and weaknesses of prognostic and predictive factors in cancer. . Section 2: Cancer prevention. 6] Stopping smoking. 7] Breast cancer. 8] Colorectal cancer. 9] Skin cancer. 10] Cervix cancer. 11] Hepatocellular cancer. 12] Diet and alcohol in cancer prevention. . Section 3: Screening for cancer. 13] breast cancer. 14] cervical cancer. 15 Colorectal cancer. 16] Prostate cancer. 17] Ovarian cancer. 18] Lung cancer. 19] Stomach cancer. 20] Melanoma. Section 4: Management of tumours of the respiratory system. 21] Non-small cell lung cancer. 22] Small cell lung cancer. 23] mesothelioma. Section 5: Management of head and neck cancers. 24] Oral and salivary gland cancers. 25] Nasoparyngeal cancers. 26] Laryngeal cancers. Section 6: Management of tumours of the gastrointestinal system. 27] Oesophageal cancer. 28] Stomach cancer. 29] Pancreatic cancer. 30] Hepatobiliary cancers. 31] Small bowel cancers. 32] Cancer of the colon and rectum. 33] Anal cancer. Section 7: Management of tumours of the urogenital system. 34] Kidney cancer. 35] Bladder cancer. 36] Prostate cancer. 37] Penile cancer. 38] Testicular Germ cell cancer. Section 8: Management of tumours of the female reproductive system. 39] Ovarian, primary peritoneal and fallopian tube cancers. 40] Cancer of the endometrium. 41] Cancer of the cervix. 42] Cancer of the vagina. 43] Cancer of the vulva. 44] Ovarian germ cell tumours. 45] Gestational trophoblastic tumours. 46] Uterine sarcomas. Section 9: Management of breast cancer. 47] Early breast cancer. 48] Advanced or recurrent breast cancer. Section 10: Management of skin cancer. 49] Cutaneous melanoma. 50] Basal cell cancer. 51] Squamous cancer of the skin. 52] Kaposi s sarcoma. Section 11: Management of sarcomas. 53] Soft tissue sarcomas. 54] Bone sarcomas. Section 12: Management of central nervous system cancers. 55] Central nervous system tumours. Section 13: Management of tumours of the eye and associated structures. 56] Uveal melanoma. 57] Orbital and adnexal tumours. . Section 14: Management of the elderly and those with co-morbid conditions. 58] Evidence on adjusting treatment of cancer to take into account co-morbidity. Section 15: Palliative management of cancer. 59] Assessing the needs of cancer patients. 60] Managing pain from cancer. 61] Managing other common symptoms of cancer. Section 16: Managing complications of cancer and its treatment. 62] Managing neutropenia, sepsis and thrombocytopenia. 63] Managing venous thrombosis and pulmonary embolism. 64] Serous effusions. 65] Metabolic complications. 66] Disseminated intravascular coagulation. 67] Spinal metastatic disease and pathological fractures... Section 17: Assessing the evidence for new treatments under development. 68] Vaccines for cancer. 69] Small molecules and targeted therapies. 70] New cytotoxic agents. 71] Hadron radiotherapy. 72] Scheduling and techniques used to deliver higher radiation doses Section 18: Complementary and alternative treatments for cancer. 73] Evidence-based assessment of CAM treatments. Section 19: Assessing how is cancer care best delivered. 74] Optimising delivery of cancer care. Section 20: Aids in delivering evidence-based care. 75] Essential materials for helping deliver care and sources of addition support